MX2019004621A - Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. - Google Patents

Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.

Info

Publication number
MX2019004621A
MX2019004621A MX2019004621A MX2019004621A MX2019004621A MX 2019004621 A MX2019004621 A MX 2019004621A MX 2019004621 A MX2019004621 A MX 2019004621A MX 2019004621 A MX2019004621 A MX 2019004621A MX 2019004621 A MX2019004621 A MX 2019004621A
Authority
MX
Mexico
Prior art keywords
bispecific antibody
multiple myeloma
combined use
treating multiple
antibody against
Prior art date
Application number
MX2019004621A
Other languages
English (en)
Spanish (es)
Inventor
Strein Klaus
Diem VU Minh
David Lourenço Paiva Bruno
Fernando San Miguel Izquierdo Jesús
Original Assignee
Engmab Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engmab Sarl filed Critical Engmab Sarl
Publication of MX2019004621A publication Critical patent/MX2019004621A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019004621A 2016-11-02 2017-11-02 Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. MX2019004621A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16196874 2016-11-02
PCT/EP2017/078109 WO2018083204A1 (en) 2016-11-02 2017-11-02 Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma

Publications (1)

Publication Number Publication Date
MX2019004621A true MX2019004621A (es) 2019-11-28

Family

ID=57226831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004621A MX2019004621A (es) 2016-11-02 2017-11-02 Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.

Country Status (14)

Country Link
US (3) US11124577B2 (enExample)
EP (2) EP4295918A3 (enExample)
JP (1) JP7267914B2 (enExample)
KR (1) KR102687833B1 (enExample)
CN (1) CN110167964B (enExample)
AU (1) AU2017353427A1 (enExample)
BR (1) BR112019008426A2 (enExample)
CA (1) CA3041183A1 (enExample)
CL (1) CL2019001198A1 (enExample)
EA (1) EA201990787A1 (enExample)
IL (1) IL266424B2 (enExample)
MX (1) MX2019004621A (enExample)
SG (1) SG11201903359RA (enExample)
WO (1) WO2018083204A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
KR20190080992A (ko) 2015-05-21 2019-07-08 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
IL260920B (en) 2016-02-03 2022-09-01 Amgen Res Munich Gmbh Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
CN116284402A (zh) 2016-12-21 2023-06-23 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CA3065951A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
WO2019053613A2 (en) * 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
PL3694529T3 (pl) 2017-10-13 2024-12-16 Harpoon Therapeutics, Inc. Trójswoiste białka i sposoby zastosowania
CA3089230A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
JOP20200292A1 (ar) * 2018-05-16 2020-11-15 Stichting Vumc Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
SG11202011545YA (en) * 2018-05-23 2020-12-30 Celgene Corp Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
EP3777895A4 (en) * 2018-06-26 2021-12-22 ABL Bio Inc. ANTI-BCMA ANTIBODIES AND ASSOCIATED USE
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
WO2020018825A1 (en) 2018-07-19 2020-01-23 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with bcma specificity and uses thereof
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN109053892B (zh) * 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
US11529339B2 (en) * 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
WO2020089437A1 (en) * 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
US12497439B2 (en) 2019-01-07 2025-12-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2020219978A1 (en) * 2019-04-25 2020-10-29 Celgene Corporation Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
AU2020307471A1 (en) * 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
CN115279459A (zh) * 2019-11-05 2022-11-01 百时美施贵宝公司 使用针对bcma和cd3的抗体的治疗方法
AU2020381349A1 (en) * 2019-11-05 2022-04-28 F. Hoffmann-La Roche Ag Treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide
SMT202400373T1 (it) 2019-11-11 2024-11-15 Amgen Inc Regime di dosaggio per agenti anti-bcma
MX2022006714A (es) 2019-12-06 2022-08-08 Regeneron Pharma Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos.
AU2021263926A1 (en) * 2020-04-29 2023-01-19 Teneoone, Inc. Methods of treating multiple myeloma
MX2022014166A (es) * 2020-05-11 2022-12-02 Janssen Biotech Inc Metodos para tratar el mieloma multiple.
WO2021229507A2 (en) * 2020-05-13 2021-11-18 Pfizer Inc. Methods, therapies and uses for treating cancer
WO2021234560A1 (en) * 2020-05-19 2021-11-25 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
MX2023003034A (es) * 2020-09-14 2023-04-10 Pfizer Metodos, terapias y usos para tratar el cancer.
JP2023543152A (ja) 2020-09-18 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
CN112159476B (zh) * 2020-10-10 2022-08-02 中国药科大学 一种用于多发性骨髓瘤的双特异性抗体及其应用
WO2022135468A1 (zh) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗bcma×cd3双特异性抗体及其用途
HRP20250696T1 (hr) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. Sastavi i postupci za liječenje sindroma oslobađanja citokina
EP4324853A4 (en) * 2021-04-15 2025-07-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd MULTI-SPECIFIC ANTIBODY TARGETING BCMA
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
IL312503A (en) * 2021-11-03 2024-07-01 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023198060A1 (zh) * 2022-04-12 2023-10-19 正大天晴药业集团股份有限公司 蛋白酶体抑制剂与抗pd-1抗体的药物组合
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
US20240228650A9 (en) 2022-05-06 2024-07-11 Ichnos Sciences SA CD3/BCMA/CD38 Trispecific Antibodies
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
WO2024191322A1 (en) * 2023-03-10 2024-09-19 Joint Stock Company "Biocad" Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025240287A1 (en) * 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU722668B2 (en) 1994-12-30 2000-08-10 King's College London Methods for producing immunoglobulins containing protection proteins in plants and their use
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2176574T3 (es) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CN1342202A (zh) 1999-01-07 2002-03-27 津莫吉尼蒂克斯公司 可溶性受体br43×2和应用方法
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
WO2002030954A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
ES2337986T3 (es) 2001-08-10 2010-05-03 Aberdeen University Dominios de union de antigenos de peces.
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
DE60127143T2 (de) 2001-11-14 2007-11-15 Affimed Therapeutics Ag Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
PL222220B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Komórka gospodarza i sposób wytwarzania polipeptydu w komórce gospodarza
PT1599504E (pt) 2003-02-25 2015-03-02 Vaccibody As Anticorpo modificado
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005118629A1 (en) 2004-06-02 2005-12-15 Diatech Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
PL1699826T3 (pl) 2005-01-05 2009-08-31 F Star Biotechnologische Forschungs Und Entw M B H Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
KR20080068004A (ko) 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
KR101460932B1 (ko) 2005-08-26 2014-11-12 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
CN103554260A (zh) 2005-10-12 2014-02-05 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
JP2009538273A (ja) 2006-04-14 2009-11-05 トルビオン ファーマシューティカルズ， インコーポレイテッド 改造されたＦＣエフェクター機能を持つ、免疫グロブリン・ヒンジ領域とＦｃ領域とを備える結合タンパク質
IL177158A0 (en) 2006-07-30 2008-01-20 Assaf Klar Method for designing and implementing improved longitudinal flexibility multilayered pipeline
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
CA2682626A1 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
FI2155783T4 (fi) 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
HUE040467T2 (hu) 2007-04-03 2019-03-28 Amgen Res Munich Gmbh Keresztfaj-specifikus kötõdomén
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN101918451A (zh) 2008-01-15 2010-12-15 弗·哈夫曼-拉罗切有限公司 抗CCR5的afucosylated抗体及其用途
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2718942A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP2283355A2 (en) 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
WO2010037836A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
ES2582603T5 (es) 2008-10-01 2022-12-02 Amgen Res Munich Gmbh Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
SI2406284T1 (sl) 2009-03-10 2017-01-31 Biogen Ma Inc. Anti-bcma protitelesa
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
GB0914330D0 (en) * 2009-08-17 2009-09-30 Univ Dublin City A method of predicting response to thalidomide in multiple myeloma patients
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
BR112013006769B1 (pt) 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
BR122022000334B1 (pt) 2011-08-01 2023-03-21 Genentech, Inc Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
MX394639B (es) 2012-04-11 2025-03-24 Us Health Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
ES2621377T3 (es) 2012-11-05 2017-07-03 Morphosys Ag Anticuerpo marcado radiactivamente y usos del mismo
JP2016507523A (ja) * 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
ES2827679T3 (es) 2013-08-20 2021-05-24 Merck Sharp & Dohme Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
AU2014368383B2 (en) 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
MA40510A (fr) * 2014-08-04 2017-06-14 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CA2960490A1 (en) 2014-09-08 2016-03-17 Celgene Corporation Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
WO2017002145A1 (en) * 2015-06-30 2017-01-05 Nec Corporation Base station, communication system, method, and program
CN108350073B (zh) * 2015-08-03 2022-03-18 英格玛布有限责任公司 针对bcma的单克隆抗体

Also Published As

Publication number Publication date
US11124577B2 (en) 2021-09-21
EP4295918A3 (en) 2024-03-20
JP2020500181A (ja) 2020-01-09
KR20190086477A (ko) 2019-07-22
SG11201903359RA (en) 2019-05-30
CA3041183A1 (en) 2018-05-11
KR102687833B1 (ko) 2024-07-24
CN110167964A (zh) 2019-08-23
EP4295918A2 (en) 2023-12-27
CN110167964B (zh) 2023-12-01
US20220017631A1 (en) 2022-01-20
BR112019008426A2 (pt) 2019-09-03
US20190263920A1 (en) 2019-08-29
EP3535295A1 (en) 2019-09-11
WO2018083204A1 (en) 2018-05-11
IL266424B2 (en) 2023-09-01
CL2019001198A1 (es) 2019-07-05
AU2017353427A1 (en) 2019-05-16
US20220002427A1 (en) 2022-01-06
IL266424A (en) 2019-06-30
IL266424B1 (en) 2023-05-01
JP7267914B2 (ja) 2023-05-02
EA201990787A1 (ru) 2019-12-30

Similar Documents

Publication Publication Date Title
MX2019004621A (es) Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
ZA201901066B (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11202011306TA (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
ZA201801789B (en) Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
IL259082A (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
ZA201708306B (en) Bispecific antibody constructs binding egfrviii and cd3
SMT202000139T1 (it) Anticorpi monoclonali contro l'antigene umano di maturazione delle cellule b (bcma)
WO2015006749A3 (en) Bispecific cd3 and cd19 antigen binding contructs
SG10201911548QA (en) Bispecific antibody constructs binding dll3 and cd3
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
HUE067160T2 (hu) Bispecifikus antitestek CEACAM5 és CD3 ellen
HK40096481A (zh) 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
HK40006116A (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
HK40047539A (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
HK40006696A (en) Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma